Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers

英国和南非严重急性呼吸综合征冠状病毒2 (SARS-CoV-2) 变种在接种过BNT162b2疫苗或已康复的2019冠状病毒病 (COVID-19) 医护人员中的中和异质性

阅读：1
作者：Marot,Stéphane,Malet,Isabelle,Leducq,Valentin,Abdi,Basma,Teyssou,Elisa,Soulie,Cathia,Wirden,Marc,Rodriguez,Christophe,Fourati,Slim,Pawlotsky,Jean-Michel,Boutolleau,David,Burrel,Sonia,Calvez,Vincent,Marcelin,Anne-Geneviève,Jary,Aude
期刊：Clinical Infectious Diseases影响因子：7.300
时间：2022起止号：2022 Mar 1;74(4):707-710
doi：10.1093/cid/ciab492

Abstract

There are concerns about neutralizing antibodies' (NAbs') potency against severe acute respiratory syndrome coronavirus 2 variants. Despite decreased NAb titers elicited by BNT162b2 vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCWs) had an NAb titer ≥1:10. In contrast, 6 months after coronavirus disease 2019 mild forms, only 9/15 (60%) of HCWs displayed detectable NAbs against 501Y.V2 strain.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。